Drug Discovery & Pharmaceuticals

RSS

Antihistamines offer new hope for erythropoietic protoporphyria-related liver disease

Chlorcyclizine shows promise in reducing protoporphyrin-IX accumulation and liver damage in erythropoietic protoporphyria, targeting histamine pathways.

20 Jan 2025

New research identifies metabolic targets to combat antibiotic-resistant bacterial infections

Targeting unique metabolic pathways in pathogens offers a novel approach to precision antibiotics, addressing the growing challenge of antimicrobial resistance.

17 Jan 2025

CN Bio signs strategic partnership with Primetech Corporation to establish distribution channel for OOC solutions in Japan

CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, today announced it has entered into a strategic partnership with Japanese life sciences research equipment distributor, Primetech.

From CN-Bio 15 Jan 2025

Enhanc3D Genomics launches suite of 3D multi-omics solutions to accelerate drug development

Enhanc3D Genomics (‘Enhanced’), an innovator in 3D genomics technology, today announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug discovery.

From Enhanc3D Genomics 15 Jan 2025

Study uncovers mechanism for cognitive improvement in dementia

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the initial cognitive damage caused by dementia, and explains how it works

15 Jan 2025

UQ and Vaxxas win global prize to accelerate patch-based mRNA vaccine for COVID-19

The University of Queensland's BASE facility – within the Australian Institute for Bioengineering and Nanotechnology (AIBN) – and Brisbane-based biotechnology company Vaxxas have been announced as stage winners of a prestigious global prize to accelerate a patch-based mRNA vaccine for COVID-19.

13 Jan 2025

COVID-19 vaccine developed by Brazilian researchers shows promise in mice

Studies conducted in mice have shown that the COVID-19 vaccine being developed by researchers at the University of São Paulo's Medical School (FM-USP) in Brazil is safe and efficacious.

13 Jan 2025

Menarini Group signs licensing deal with Insilico for promising cancer treatment

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.

10 Jan 2025

New research reframes the debate on drug development costs

The typical cost of developing new medications may not be as high as generally believed, with a few ultra-costly medications skewing public discussions about the cost of pharmaceutical research and development, according to a new RAND study.

8 Jan 2025

AI-designed drug shows promise for inflammatory bowel disease

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announces positive results from two Phase I studies in Australia and China of ISM5411, a novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico's Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory Bowel Disease (IBD).

8 Jan 2025

Insilico Medicine nominates ISM1745 as preclinical candidate for MTAP-deleted cancers

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced the nomination of ISM1745, a potentially best-in-class MTA cooperative PRMT5 inhibitor with AI-powered novel scaffold, as preclinical candidate (PCC) for the treatment of MTAP-deleted cancers.

2 Jan 2025

New SIMPL2 platform revolutionizes the study of protein-protein interactions

A team led by researchers at the University of Toronto has created a platform, called SIMPL2, that revolutionizes the study of protein-protein interactions by simplifying detection while improving measurement accuracy.

23 Dec 2024

New modular strategy reduces piperidine synthesis steps for pharmaceuticals

A team of chemists from Scripps Research and Rice University has unveiled a novel method to simplify the synthesis of piperidines, a key structural component in many pharmaceuticals. The study, published in Science, combines biocatalytic carbon-hydrogen oxidation and radical cross-coupling, offering a streamlined and cost-effective approach to create complex, three-dimensional molecules. This innovation could help accelerate drug discovery and enhance the efficiency of medicinal chemistry.

20 Dec 2024

Photocatalysed flow method accelerates synthesis of potent MC4R antagonist

Asynt report that the Cresswell Group, led by Dr Alexander J. Cresswell at the University of Bath (UK), have demonstrated the synthesis of novel spirocyclic tetrahydonaphthyridines (THNs) expanding the chemical space of these important scaffolds for drug discovery.

From Asynt 17 Dec 2024

Novel drug holds promise for treating Duchenne muscular dystrophy

A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle degeneration.

16 Dec 2024

Addressing inequities in cardiovascular drug access

A new study assessing provincial and territorial variations in reimbursement criteria of drug coverage for patients covered by Canada's public pharmacare programs for two common cardiovascular conditions revealed significant inequities and deficiencies in access to medications and treatment.

12 Dec 2024

New tool accelerates drug discovery

The development of molecules to study and treat disease is becoming increasingly burdened by the time and specificity required to analyze the vast amounts of data generated by synthesizing large collections of new molecules.

12 Dec 2024

New class of antivirals shows promise against multiple viruses

The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic - an effective antiviral that has since successfully treated millions.

11 Dec 2024

Exploring the Future of Neuroscience Drug Discovery

Innovative iPSC models are transforming neuroscience drug discovery and research.

From Charles River Labs - Neuroscience Discovery Services 11 Dec 2024

Newcells Biotech raises additional funding from investors

Newcells Biotech (“Newcells”), a leading drug discovery partner specializing in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, today announced it has raised a further £1.2 m from existing investors Mercia Ventures, Northstar Ventures and North East Finance.

From Newcells Biotech 8 Dec 2024